Evelo Biosciences Inc reports results for the quarter ended in June - Earnings Summary

Evelo Biosciences

11/08/2022 14:31

* Evelo Biosciences Inc  EVLO.OQ  reported a quarterly
adjusted
loss of 40 cents​​ per share for the quarter ended in June. The
mean expectation of six analysts for the quarter was for a loss
of 43 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Evelo Biosciences Inc's reported EPS for the quarter was a
loss
of 40 cents​.
    * The mean earnings estimate of analysts had risen by
about 14% in
the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Evelo Biosciences Inc shares had risen by 39.8% this
quarter and
lost 51.4% so far this year.
    * The company reported a quarterly loss of $30.56 billion.
    * Wall Street's median 12-month price target for Evelo
Biosciences
Inc is $13.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 11
at 01:31 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -0.43          -0.40          Beat
 Mar. 31 2022      -0.58          -0.56          Beat
 Dec. 31 2021      -0.61          -0.54          Beat
 Sep. 30 2021      -0.54          -0.63          Missed